TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed inform consent prior to any study-mandated procedures~2. Adult patients 18-80 years of age~3. World Health Organization Group 1 PAH associated with scleroderma (SSc-PAH)~4. WHO functional Class II-III~5. 6MWD 150 to 450 meters~6. Right heart catheterization demonstrating mPAP≥ 25 mmHg and PCWP or left ventricular end diastolic pressure ≤15mm Hg and pulmonary vascular resistance ≥240 dynes/cm-5 (3 Wood units) within 12 weeks prior to study entry.~7. ACR defined systemic sclerosis~Exclusion Criteria:~1. Pulmonary hypertension associated with~   * PAH of any etiology other than scleroderma~  * PH of any etiology other than WHO Group I PAH~  * Pulmonary venous hypertension defined as PCWP or LVEDP \>15 mHg~  * Untreated sleep apnea with AHI \>20 or SaO2 Nadir \<87%~  * Chronic thromboembolic disease~  * Sarcoidosis~2. Participation in a clinical investigational study within the previous 30 days~3. Moderate to severe hepatic impairment (e.g., Child-Pugh Class B or C)~4. Renal failure defined as:~   * estimated creatinine clearance \<30 m/min~  * serum creatinine\>2.5 mg/dl~5. Serum aspartate aminotransferase (AST) and or alanine aminotransferase (ALT) \> 1.5 times the upper limit of normal~6. Systolic blood pressure \< 90mmHg~7. Recently started (\< 8 weeks prior to randomization) or planned cardiopulmonary rehabilitation program based on exercise~8. Pregnant or lactating women~9. Need for HAART therapy~10. Planned treatment or treatment with another investigational drug within 1 month prior to start~11. Moderate to severe interstitial lung disease, defined by FVC \< 80% or evidence on HRCT of fibrosis or ground glass changes involving more than 30% of lung parenchyma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dimethyl Fumarate (DMF) (Type: ACTIVE_COMPARATOR): Twice daily oral doses of Dimethyl Fumarate (DMF) 120mg for the first 7 days followed by the maintenance dose of Dimethyl Fumarate (DMF) 240mg twice a day. Subjects will be dosed for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Twice daily oral doses of placebo for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of AF Ablation Induced Thrombo-Embolic Incidence Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Electrocardiographically documented, symptomatic paroxysmal AF.~* Patients with indication for left atrial ablation of AF according to ESC guidelines for the management of atrial fibrillation.~* Anticoagulation according to clinical routine using coumarin derivates with target INR between 2.0 and 3.0 at least 3 weeks prior to the scheduled ablation procedure or novel oral anticoagulants (NOACs).~* Geographically stable for the duration of the study.~* Willingness and ability to perform written informed consent~Exclusion Criteria:~* Long standing persistent or persistent AF~* CHA2DS2-VASc score ≥ 5~* Prior ischemic stroke or Transient Ischemic Attack~* Previous Pulmonary Vein ablation~* Contraindication for anticoagulation therapy~* Contraindication for Diffusion-Weighted MRI~* Claustrophobia~* Contraindication for transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE, if TEE not possible)~* Implanted cardiovascular device, including but not limited to an atrial or ventricular pacemaker or defibrillator leads, artificial valves, stents, septal or LAA occluders~* Acute coronary syndrome \< 3 months prior to scheduled ablation~* Moderate to severe valvular heart disease~* LA size \> 55 mm (confirming echo at maximum 3 months old)~* Patients with non-controlled heart failure or patients with current and recent (\< 1 month prior to ablation) heart failure~* Ejection fraction \< 35% (confirming echo at maximum 3 months old)~* Conditions that prevent patient's participation in neurocognitive assessment (at physician's discretion)~* Female patients who are pregnant or breast feeding or plan a pregnancy during the course of the study~* Any limitation to contractual capability~* Simultaneous participation in another study~* Age \< 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): All patients undergo cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Transesophageal (or Intracardial) Echocardiography and paperbased neurocognitive testing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects of non-childbearing potential and male subjects between the ages of 40 and 80 years, inclusive~* Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD and who meet the criteria for Stage II-III disease~* Subjects must have a smoking history of at least 10 pack-years~Exclusion Criteria:~* Current evidence or history within the previous 6 months of any clinically significant disease (other than COPD) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data~* A COPD exacerbation requiring treatment with oral steroids or hospitalization for the treatment of COPD within 3 months of Screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Double blind placebo for PF-03715455
- PF-03715455 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: APE-Study: Ablation of Barrett's Mucosa vs. Surveillance Without Ablation in Patients Cured From Barrett's Cancer Combined With Randomization of Esomeprazole vs. Placebo for Symptomatic Reflux Control After Successful Barrett's Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Endoscopically and histologically complete remission of mucosal Barrett's cancer (endoscopic resection with or without thermal ablation of resection margins)~* Initial length of Barrett's segment before cancer therapy \> 3 cm (initially long-segment Barrett's esophagus)~* Barrett's length after endoscopic therapy of Barrett's cancer \> 2 cm~* Informed consent of the patient~Exclusion Criteria:~* Attempted ablation therapy before the trial~* Treatment duration of early Barrett's cancer \> 12 months~* Duration between achievement of complete remission and attempted inclusion into the study \> 24 months~* The Barrett's cancer treated has already been a secondary lesion of earlier Barrett's cancer~* Inadequate healing of endoscopic resection (ER) ulcers~* No residual Barrett's mucosa observed after pretreatment with ER~* No PPI compliance~* Relevant comorbidity (e.g., malignancy)~* Pregnancy~* Age below 18 years~* Patient not able to understand study characteristics~* No written informed consent available~* Allergy against esomeprazole or intolerance of medication ingredients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ablation of Barretts with concomitant esomeprazole therapy (Type: OTHER): comparison of recurrence-free survival
- non ablation (Type: NO_INTERVENTION): non ablation only surveillance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women \>/= 18 years with histologically proven metastatic breast cancer~* No prior chemotherapy in the advanced situation~* ECOG \</= 2~* Adequate bone marrow reserve~* left ventricular ejection fraction (LVEF) \>/= 50, measured within 4 weeks before study treatment~* Existence of written informed consent~Exclusion Criteria:~* Previous high dose therapy with stem cell support~* Prior adjuvant treatment with cumulative anthracycline dose of 600 mg/m² Epirubicin, 300 mg/m² Doxorubicin, 80 mg/m² Mitoxantrone~* Concomitant hormon- or chemotherapy or radiation therapy~* Her2/neu overexpression~* pregnancy or breast feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Myocet/Paclitaxel (Type: EXPERIMENTAL): 20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study to Collect Clinical Data to Document Clinical Performance and Safety in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* For the HLS-1, HLS-2, HLS Evolution and HLS Noetos retrospective group:~  1. Adult patients older than 18 years old.~ 2. Patients who have undergone routine preoperative clinical evaluations prior to their Total Knee Replacement surgery and implanted with one of the following prostheses from the HLS range: HLS-1, HLS-2, HLS Evolution and HLS Noetos between their first date of use in 1987 and their last date of use as normal practice at the participating site in accordance to indications and intended use as described in the Instruction for Use (IFU) of the study devices.~ 3. Patients who have been informed about their participation into an observational study.~For the HLS KneeTec prospective group (with retrospective surgeries):~1. Adult patients older than 18 years old.~2. Patients who have undergone routine preoperative clinical evaluations and received a TKR or are suitable candidates for a TKR with a fixed or mobile postero-stabilized HLS KneeTec prosthesis (cementless, cemented or hybrid combination) for the treatment of a primary or secondary knee osteoarthritis and inflammatory disease such as rheumatoid arthritis in accordance to indications and intended use as described in the Instruction for Use (IFU) of the study devices.~3. Patients who are willing and able to complete the scheduled FU visits.~4. Patients who have been informed about their participation into an observational registry study~Exclusion Criteria:~* Patients mentally incompetent or unable to understand what participation in the study entails.~* Patients who present signs and symptoms of any of the known contraindications described in the Instruction for Use (IFU) of the study devices.~* Patients who deny their participation into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Systemic Lupus Erythematosus (SLE) as defined by meeting at least 4 of the 11 classification criteria of the American College of Rheumatology for the classification of Systemic Lupus Erythematosus, either sequentially or coincident. The 4 criteria need not be present at study entry~* Renal biopsy within 12 months prior to screening visit indicating active proliferative lupus glomerulonephritis (met ISN/RPS Class III or IV classification criteria \[2003\], excluding Class III \[C\], IV-S \[C\] and IV-G \[C\], or the World Health Organization Class III or IV classification criteria \[1982\], excluding Class IIIc, IVd). If the renal biopsy was performed \>3 months but ≤12 months prior to screening visit, at least 1 of the following 3 serologies (performed locally) must have been abnormal prior to screening visit: complement (C3 or C4) level below normal range OR anti-dsDNA \>upper limit of normal range.~* A stable serum creatinine ≤3 mg/dL~Exclusion Criteria:~* Subjects with a rise in serum creatinine of ≥1 mg/dL within 1 month prior to the screening visit~* Subjects with drug-induced SLE, as opposed to idiopathic SLE~* Subjects with severe, unstable and/or progressive Central nervous system (CNS) lupus~* Subjects with autoimmune disease other than SLE as their main diagnosis (e.g.; Rheumatoid arthritis (RA), Multiple Sclerosis \[MS\])~* Subjects who have received treatment with cyclophosphamide within 3 months of randomization (Day 1).~* Subjects who have received treatment with rituximab \< 6 months prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept 30 mg/kg+Corticosteroids+MMF (Type: EXPERIMENTAL): Short-term Period
- Abatacept 10 mg/kg+Corticosteroids+MMF (Type: EXPERIMENTAL): Short-term Period
- Placebo+Corticosteroids+MMF (Type: EXPERIMENTAL): Short-term Period
- Abatacept 10mg/kg (Type: EXPERIMENTAL): Long-term Extension Period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Early Rehabilitation for Breast Cancer - A Randomized Control Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible participants include adult female patients, ≥18 years of age, with a primary first-time diagnosis of breast cancer, and referred on or after January 1, 2021 for mastectomy surgery.~Exclusion Criteria:~* Women will be excluded if they will have bilateral surgery, breast-conserving surgery, recurrence of breast cancer, stage IV, or neoadjuvant treatment prior to surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Physical Therapy Intervention (Type: EXPERIMENTAL): Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning \~4 weeks after surgery (x̄=10 visits).
- Usual Care (Type: NO_INTERVENTION): The usual care group will be instructed to continue with their typical daily activities.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of the MedSentry System on Medication Adherence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have successfully completed the Partners Connected Cardiac Care Program (CCCP)~* Take at least 3 and no more than 10 different daily medications (including both prescription and non-prescription/over the counter medications) to treat Heart Failure (HF) and other comorbid disorders.~* Take medications no more than 4 specified times each day (i.e. morning, afternoon, early evening, bedtime).~* The patient must be able to open a pill bottle independently.~* The patient must be able to sort and manage their own medications.~* Hospitalization within the last 24 months.~* Have a telephone or cell phone.~* Live in the greater Boston area.~* The patients must speak, read and write English.~* The patients must not be either vision or hearing impaired (i.e., unable to hear an alarm similar to a clock alarm or oven alarm).~* Patient must have an Massachusetts General Hospital (MGH) affiliated care provider.~Exclusion Criteria:~* Dementia or other conditions precluding the participant from providing informed consent or from learning to use the MedSentry pillbox.~* Home environment unsuitable for the MedSentry pillbox and other installed equipment.~* Awaiting revascularization, cardiac resynchronization or heart transplant.~* Patients with a coexisting terminal illness like cancer or Chronic Renal Failure (CRF) requiring dialysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Subjects will continue to receive usual medical care from their doctor(s).
- MedSentry System (Type: EXPERIMENTAL): Subjects will continue to receive usual medical care from their doctor(s). Subjects will use the MedSentry System and electronic pillbox, to manage their medications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (≥18 years old) patients undergoing BAE for the evaluation of OGIB or iron deficiency anemia.~Exclusion Criteria:~* Unable to provide written informed consent.~* Pregnancy or lactation.~* Suspected bowel obstruction or GI perforation.~* Unable to tolerate sedation or general anesthesia due to medical co-morbidities.~* Uncorrected coagulopathy (platelet count \<50,000, INR\> 2, PTT\> 2x upper limit of normal).~* Patient undergoing retrograde BAE.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- No cap (Type: PLACEBO_COMPARATOR): enteroscopy performed without a cap
- Enteroscopy with a cap (Type: ACTIVE_COMPARATOR): Enteroscopy performed with a CAP fitted to the end of the scope

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed SCLC who presented with Limited Stage (LS) at diagnosis.~* Measurable disease at the time of initial therapy~* Appropriate treatment for LS-SCLC including radiotherapy and chemotherapy.~* Responsive disease to standard chemoradiation therapy as defined by RECIST~* Patients with CR after chemoradiation therapy are strongly recommended to be treated with prophylactic cranial irradiation~* CBC with an absolute neutrophil count (ANC) \>/= 1,000/uL, hemoglobin \>/= 8.0 g/DL and platelet count \>/= 75,000/uL.~* Normal prothrombin time (PT) and partial thromboplastin time (aPTT), unless on monitored anticoagulation therapy for medical conditions not excluded in the trial.~* Liver enzymes: total bilirubin less than or equal to 2mg/dL; AST and ALT less than 1.5X the upper limit of normal.~* Creatinine clearance of \>/= 60 mL/min~* Pulmonary: DLCO greater than 50%~* Cardiac: left ventricular ejection fraction greater than 45%~Exclusion Criteria:~* Patient with stable (SD) or progressive disease (PD) after 4 cycles of standard cisplatin and etoposide and concurrent chest irradiation~* Pregnant or lactating woman~* HIV infection confirmed by NAT~* Common variable immunodeficiency~* Active CNS malignancy~* Active bacterial, fungal or viral infection~* Unfavorable psychosocial evaluation or history of poor compliance to prescribed medical care~* Prior history of autologous or allogeneic hematopoietic cell transplantation~* Presence of protocol specific comorbid conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- adeno virus vectored p53 (Type: EXPERIMENTAL): Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues